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Atrial fibrillation increases 5-fold the risk of ischemic stroke.1 Vitamin K antagonists (VKAs) have long been 
the reference treatment for stroke prevention, with a risk of se-
rious bleeding.2–5 The direct-acting oral anticoagulant rivarox-
aban was approved for stroke prevention in nonvalvular atrial 
fibrillation (NVAF) in 2012.6 In the ROCKET-AF pivotal trial 
(Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition 
Compared With Vitamin K Antagonism for Prevention of 
Stroke and Embolism Trial in Atrial Fibrillation), patients 
were randomized to rivaroxaban 20 mg (R20) daily or 15 mg 
in patients with a low creatinine clearance (about 20% of the 
participants).7 Patients randomized to rivaroxaban had fewer 
stroke and systemic embolisms (SSEs) than patients random-
ized to warfarin without significant difference in clinically rel-
evant bleeding (CRB) or major bleeding (MB).7 There was 
no separate description of rivaroxaban 15 mg (R15) or R20 
patients or results.
The translation of clinical trial results to actual practice is 
uncertain because physicians, patients, drug prescriptions, and 
usage may not be the same.8–10 Few observational studies have 
compared standard and reduced doses of rivaroxaban versus 
VKA.11 Studies in Asian patients concerned lower doses.12,13
When rivaroxaban was first marketed in France in 2012, 
regulatory authorities requested a comparative effectiveness 
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and safety study of R20 or R15 in NVAF, compared with 
VKA. To this end, we performed the study reported herein
Research Question and Objectives
To compare the 1-year event rates of SSE, MB, and all-cause 
death in new users of R15 or R20 versus VKA for NVAF.
Methods
The data used in this study are public, provided by the French National 
Healthcare System (Système National des Données de Santé [SNDS]).14 
The data can be accessed in our department. Alternatively, readers may 
request the same dataset from SNDS at https://www.indsante.fr.
Study Design
High-dimensional propensity score (hdPS)–matched cohorts study of 
new users of R20 versus VKA and R15 versus VKA for NVAF in 
SNDS in 2013 or 2014, followed for 1 year.
The full study protocol, as approved by the regulatory authori-
ties, which requested the study, can be found at http://www.encepp.
eu/encepp/openAttachment/fullProtocolLatest/26842.
Setting
SNDS is the national healthcare data system in France. It links the 
mandatory public health insurance system claims database to the hos-
pital discharge database and the death registry.14 It includes >99% of 
the French population (66 million people) from birth (or immigration) 
to death (or emigration), irrespective of socioeconomic status even 
if a person changes occupation or retires. SNDS contains individual 
anonymized information on all medical and paramedical encounters, 
drug claims, hospital admission diagnoses and procedures, and date 
of death, which are linked to create a longitudinal record of health 
encounters (inpatient or outpatient) from private or public hospitals 
and from private practice.14
SNDS has been used to perform real-life studies comparing 
direct-acting oral anticoagulant to warfarin or to each other.15–18 It is 
described elsewhere.14
In brief, all prescribed drug dispensings are recorded with the 
drug’s Anatomical Chemical Therapeutic Classification code, the 
strength, the number of tablets per pack, and the number of packs. 
All medical and paramedical encounters are recorded, as are all labo-
ratory tests. Chronic diseases that warrant full coverage are recorded 
(International Classification of Diseases, Tenth Revision). Hospital 
admissions are recorded including main and secondary diagnoses 
(International Classification of Diseases, Tenth Revision), in-hospital 
procedures, and expensive drugs.
Regular internal and external quality assurance processes verify 
the validity of the diagnostic coding.19 For instance, the positive pre-
dictive values of codes for stroke, myocardial infarction, or heart 
failure are above 80% to 90%.20–22
Subjects
All adults with a dispensing of any oral anticoagulant in 2013 or 
2014, with a diagnosis of definite NVAF as described previously,4,15,16 
and with no dispensing of any oral anticoagulant in the previous 3 
years were identified (Figure 1).
Only the results concerning definite NVAF are presented. Results 
in probable NVAF were not different and are not shown.
Patients with rheumatic valvular heart disease or valve replace-
ment, patients with another indication for anticoagulation (deep vein 
thrombosis or pulmonary embolism, orthopedic surgery), or without 
a definite diagnosis of atrial fibrillation were excluded.
Only patients with definite NVAF, and complete datasets (3-year 
history, 1-year follow-up in the absence of death) were retained in the 
cohort study (Figure 1).
Index date was first anticoagulant dispensing between January 1, 
2013, and December 31, 2014.
Baseline Covariates
All chronic conditions, cardiovascular risk factors, previous and con-
comitant drug dispensing, and hospital admission diagnoses were 





-VASc and HAS-BLED scores (hyperten-
sion, abnormal renal and liver function, stroke, bleeding, labile INR, 
elderly, drugs or alcohol) are reported in Table 1.4,18 Codes used for 
these scores are indicated in Appendix II in the online-only Data 
Supplement. Further baseline covariates are described in Table I in 
the online-only Data Supplement for all and matched populations. 
They include a modified Charlson index predictive of mortality in 
this database.23
Exposure
The drug exposure period started at index date and ended 30 days 
after the last dispensing or at dispensing of a different anticoagulant 
(switch). Last dispensing was defined as a dispensing that was not 
followed by another dispensing of the same drug within 60 days.4
Follow-Up
Follow-up began on index date and continued until patient death, 
treatment discontinuation, occurrence of an outcome of interest (for 
that outcome), or end of study (1 year after index date), whichever 
came first. There was no loss to follow-up.
Study Outcomes
The 3 primary outcomes were hospitalization for ischemic stroke 
or systemic embolism (SSE), hospitalization for MB, and all-
cause death.
Secondary outcomes included acute coronary syndrome (myocar-
dial infarction or unstable angina), CRB, and specific bleeding sites.
Composite Outcome of SSE, MB, 
and Death Was Also Studied
MB was hospital diagnosis of intracerebral hemorrhage, critical 
organ bleeding, any CRB with blood transfusion or acute posthem-
orrhagic anemia, or death during hospital stay for bleeding event 
(International Society for Thrombosis and Hemostasis definition).24 
CRBs were all hospitalizations with a main diagnosis of bleeding. 
Specific bleeding sites were intracerebral hemorrhage, gastrointes-
tinal bleeding, urogenital bleeding, other critical organ or site bleed-
ing, and other bleeding.
The International Classification of Diseases, Tenth Revision, 
codes used to identify these outcomes are provided in Appendix III 
in the online-only Data Supplement. The same codes were used for 
other studies of anticoagulant users.4,15,16,18
Statistical Methods
All analyses were prespecified and described in a statistical anal-
ysis plan. The protocol was registered with the European Medicines 
Agency EUPAS (European Union Post-Authorization Study) 
database before start of study and is available at http://www.encepp.
eu/encepp/openAttachment/fullProtocolLatest/26842.
In brief, to reduce confounding because of imbalance in study 
covariates, hdPS matching was used.25 Unconditional binary logistic 
regression was used to estimate separately the predicted probability 
of patients initiating R15 or R20 rather than VKA,26,27 taking into 
account all the information in the database, with multiple data dimen-
sions from patient data and healthcare reimbursements during the 
3-year period before index date (see Appendix IV in the online-only 
Data Supplement). Variables were chosen for their association with 
outcomes, among other criteria including demographic variables at 





-VASc and HAS-BLED scores, hospitalization 
(other than cardioversion or catheter ablation) in the month before 
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disease, diabetes mellitus, hospital and nonhospital costs during the 
year and the month before index date, and 500 other variables26–29 
selected from 4 dimensions. The codes and variables concerned are 
listed in Appendix IV in the online-only Data Supplement.
R15 versus VKA and R20 versus VKA patients were matched 
separately on the hdPS score, using greedy nearest neighbor match-
ing. Goodness of match was assessed by the hdPS distributions in 
unmatched and matched populations (Figures I and II in the online-
only Data Supplement) and by standardized mean differences.30 An 
absolute standardized mean difference of ≤0.1 (10%) indicates a neg-
ligible difference between groups.30
The main analysis was performed in the matched patients during 
exposure (on treatment). Incidence rates were measured using event 
counts and exposed patient time and represented with Kaplan-Meier 
plots. Hazard ratio and 95% CIs of R15 versus VKA and R20 versus 
VKA were estimated using Cox proportional hazards model for death 
and the model by Fine and Gray31 for competing risks for nonfatal 
events. The number needed to observe one fewer event in one group 
compared with the other (NNO) is 1/(p[A]–p [B])×100 where p(A) 
and p(B) are event rates with treatment A and B.
Sensitivity analyses were performed on the whole population 
using adjustment on sex, age at index date, and hdPS (in deciles; 
Figures 2 and 3).
Statistical analysis was done by Bordeaux PharmacoEpi—a re-
search platform of University of Bordeaux—using SAS software 
(version 9.4; SAS Institute, NC) and the Harvard routines for hdPS 
(SAS pharmacoepi toolbox, www.drugepi.org).32
Ethics and Registration
This study was requested by the National Healthcare authorities. It 
was authorized by the Institut National des Données de Santé on 
February 1, 2016, and by the National Commission on Informatics 
and Liberties on April 8, 2016. It is registered with the EUPAS reg-
istry as EUPAS14567 (http://www.encepp.eu). Study data were 
received on November 4, 2016. Bordeaux PharmacoEpi is ISO 
9001:2015-certified for pharmacoepidemiological research.
Results
Of 719 537 new anticoagulant users in 2013 and 2014, 220 011 
had a diagnosis of NVAF; 108 666 had been dispensed VKA 
and 69 736 rivaroxaban, of whom 24 585 were dispensed R15 
and 42 531 R20 (Figure 1). Before matching, R20 patients were 
younger and at lower risk than VKA or R15 patients (Table 1).
Thirty-one thousand one hundred seventy-one R20 patients 
(73% of all R20 patients) and 23 314 R15 patients (95% of 
all R15 patients) were individually matched to the same num-
bers of VKA patients (Table 1). hdPSs were identically dis-
tributed in matched R15 and VKA or R20 and VKA patients 
(Appendix V in the online-only Data Supplement; Figures 
I and II in the online-only Data Supplement). Standardized 
mean differences in matched patients were always <5% for 
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27 352 (64.4) 11 574 (47.2) 56 349 (51.9) −25.6 9.4 19 329 (62.0) 19 329 
(62.0)
11 070 (47.5) 11 070 (47.5) 0.0 0.0
Mean age at 
index date, y
68.6 (11.1) 79.8 (9.4) 78.4 (11.0) −88.2 14.2 71.2 (10.0) 71.2 (10.0) 80.1 (8.7) 80.1 (8.7) −0.2 0.0
Minimum–
maximum
18.0–104.0 19.0–105.0 18.0–108.0   22.0–101.0 22.0–101.0 24.0–103.0 23.0–103.0   
Age at index date (in categories), y; n (%)
  <65 13 331 (31.4) 1648 (6.7) 12 892 (11.9)   7305 (23.4) 7278 (23.3) 1369 (5.9) 1380 (5.9)   
  65–80 22 544 (53.1) 8145 (33.2) 36 631 (33.7)   17 326 (55.6) 17 550 
(56.3)
7851 (33.7) 7768 (33.3)   
  ≥80 6605 (15.5) 14 736 (60.1) 59 133 (54.4)   6540 (21.0) 6343 (20.3) 14 094 (60.5) 14 166 (60.8)   
Stroke risk factors (score), n (%)
Congestive 
heart failure
5282 (12.4) 5580 (22.7) 38 534 (35.5) −56.0 −28.3 4853 (15.6) 4949 (15.9) 5467 (23.4) 5393 (23.1) −0.8 0.8
  Hypertension 14 284 (33.6) 11 084 (45.2) 60 473 (55.7) −45.4 −21.0 11 908 (38.2) 12 354 (39.6) 10 694 (45.9) 10 710 (45.9) −2.9 −0.1
  Age ≥75 y 13 678 (32.2) 19 172 (78.2) 75 405 (69.4) −80.2 20.0 12 824 (41.1) 12 930 (41.5) 18 344 (78.7) 18 325 (78.6) −0.7 0.2
  Diabetes 
mellitus
8713 (20.5) 5186 (21.1) 29 335 (27.0) −15.3 −13.7 7016 (22.5) 7285 (23.4) 4997 (21.4) 5088 (21.8) −2.1 −0.9
Stroke or TIA 
history
3735 (8.8) 2683 (10.9) 16 225 (14.9) −19.1 −11.9 3329 (10.7) 3521 (11.3) 2619 (11.2) 2654 (11.4) −2.0 −0.5
Vascular 
disease history
4645 (10.9) 4051 (16.5) 24 993 (23.0) −32.6 −16.3 4098 (13.1) 4315 (13.8) 3922 (16.8) 3989 (17.1) −2.0 −0.8
  Age, 65–74 
y
15 471 (36.4) 3709 (15.1) 20 359 (18.7) 40.4 −9.7 11 042 (35.4) 10 963 (35.2) 3601 (15.4) 3609 (15.5) 0.5 −0.1
  Women 15 128 (35.6) 12 955 (52.8) 52 307 (48.1) −25.6 9.4 11 842 (38.0) 11 842 (38.0) 12 244 (52.5) 12 244 (52.5) 0.0 0.0
CHA2DS2-VASc score (in categories), n (%)
  0 5565 (13.1) 539 (2.2) 3101 (2.9)   2546 (8.2) 2522 (8.1) 455 (2.0) 470 (2.0)   
  1 8805 (20.7) 1342 (5.5) 6957 (6.4)   5072 (16.3) 4901 (15.7) 1202 (5.2) 1195 (5.1)   
  ≥2 28 110 (66.2) 22 648 (92.3) 98 598 (90.7)   23 553 (75.6) 23 748 (76.2) 21 657 (92.9) 21 649 (92.9)   
Bleeding risk factors (score), n (%)
  Hypertension 14 284 (33.6) 11 084 (45.2) 60 473 (55.7) −45.4 −21.0 11 908 (38.2) 12 354 (39.6) 10 694 (45.9) 10 710 (45.9) −2.9 −0.1
Abnormal renal 
function
891 (2.1) 1660 (6.8) 19 538 (18.0) −54.8 −34.6 852 (2.7) 1043 (3.3) 1625 (7.0) 1651 (7.1) −3.6 −0.4
Abnormal liver 
function
579 (1.4) 397 (1.6) 3531 (3.2) −12.6 −10.6 526 (1.7) 558 (1.8) 382 (1.6) 377 (1.6) −0.8 0.2
  Stroke 
history
3107 (7.3) 2240 (9.1) 14 124 (13.0) −18.9 −12.4 2825 (9.1) 3014 (9.7) 2191 (9.4) 2214 (9.5) −2.1 −0.3
  Bleeding 
history
647 (1.5) 588 (2.4) 3658 (3.4) −12.0 −5.8 554 (1.8) 627 (2.0) 565 (2.4) 586 (2.5) −1.7 −0.6




22 611 (53.2) 15 249 (62.2) 72 275 (66.5) −27.4 −9.1 18 476 (59.3) 18 899 (60.6) 14 641 (62.8) 14 727 (63.2) −2.8 −0.8
HAS-BLED score (in categories), n (%)
  0 6106 (14.4) 630 (2.6) 2825 (2.6)   2610 (8.4) 2266 (7.3) 489 (2.1) 446 (1.9)   
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all parameters and <2% for most (Table 1; Appendix V in the 
online-only Data Supplement).
Mean drug possession ratio (percentage days covered dur-
ing exposure period) was above 80% in 93% and 94.9% of 
R15 and R20 patients, respectively. This cannot be calculated 
for VKAs, which do not have a fixed daily dose.
Outcomes
R20 patients had significantly better results for all primary 
outcomes than VKA (Table 2). Among secondary outcomes, 
CRB including intracerebral hemorrhage, and gastroin-
testinal bleeding, and acute coronary syndrome were less 
common in R20 users than in matched VKA users (Table 2; 
Figures 2 and 3).
Number needed to observe one fewer death with R20 
than with VKA was 61 and 43 to observe one fewer of any 
primary event.
There was no difference between R15 and VKA for SSE, 
but MB and all-cause death were significantly less common 
with R15 (Table 2). Among secondary outcomes, CRB in-
cluding intracerebral hemorrhage were less common with 
R15 (Figure 3).
Number needed to observe one fewer death with R15 than 
VKA was 46 and 42 to observe one fewer of any primary event.
Results were similar when analyses were done in the 
whole population, adjusted on the same parameters used for 
matching (Figures 2 and 3).
Events accrued regularly throughout the study (Appendix 
V in the online-only Data Supplement; Figures III and IV in 
the online-only Data Supplement).
Discussion
In this countrywide new user cohort study of real-life expe-
rience with standard (20 mg) or reduced (15 mg) doses of 
Figure 2. Effectiveness and safety outcomes in rivaroxaban 20 mg (R20) vs vitamin K antagonist (VKA) patients: forest plots. HR indicates hazard ratio.
  2 14 266 (33.6) 9710 (39.6) 36 637 (33.7)   11 742 (37.7) 11 985 (38.4) 9280 (39.8) 9663 (41.4)   
  3 6998 (16.5) 6722 (27.4) 33 943 (31.2)   6395 (20.5) 6746 (21.6) 6519 (28.0) 6536 (28.0)   
  >3 1640 (3.9) 2158 (8.8) 18 020 (16.6)   1581 (5.1) 1619 (5.2) 2114 (9.1) 2041 (8.8)   
More data on baseline characteristics are shown in the online-only Data Supplement. HAS-BLED indicates hypertension, abnormal renal and liver function, stroke, bleeding, 
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rivaroxaban compared with matched VKA patients with def-
inite NVAF, rivaroxaban at either dose was associated with 
better indicators of effectiveness or safety and with lower 
mortality.
The pivotal trial that compared rivaroxaban to warfarin, 
ROCKET-AF,7 did not differentiate the 2 dosages. Patients 
were randomized to R20 or R15 if they had renal disease. 
About 20% of the trial patients were on the reduced dose, 
35% here. SSEs were less common on treatment in rivarox-
aban patients than in patients randomized to VKA. Deaths 
were also less common but not significantly so (hazard ratio, 
0.85 [0.70–1.02]), with overall death rates at 1.9% to 2.2% 
per year, compared with 3.9% and 5.8% in our R20 versus 
VKA cohorts, that is, a real-life death rate about double that 
in the clinical trial.
Death rates in the older and sicker R15 and matched VKA 
patients were higher (R15, 8.1%; VKA, 10.9%). Higher death 
rates in real-life patients than in apparently similar patients 
from pivotal clinical trials33 are commonly attributed to ex-
clusion from clinical trials of patients with poor short-term 
prognosis. Signals of increased gastrointestinal bleeding in 
ROCKET-AF were not duplicated.
Our results are of the drugs as they were used, not in a 
randomized clinical trial. The results despite our best efforts 
might suffer from residual unmeasured confounding, and we 
cannot affirm causality. However, the matched cohorts were 
Table 2. Cumulative Incidence of Main Outcomes (Kaplan-Meier Estimate) During Drug Exposure in Matched R20 and VKA and Matched R15 and VKA Patients
R20, n=31 171 VKA, n=31 171  R15, n=23 314 VKA, n=23 314  
 n % (95% CI) n % (95% CI) HR (95% CI) n % (95% CI) n % (95% CI) HR (95% CI)
SSE 372 1.5 (1.4–1.7) 494 1.9 (1.8–2.1) 0.79 (0.69–0.90) 399 2.3 (2.0–2.5) 419 2.1 (1.9–2.3) 1.05 (0.92–1.21)
MB 359 1.5 (1.4–1.7) 560 2.2 (2.1–2.4) 0.67 (0.59–0.77) 426 2.4 (2.2–2.6) 560 2.9 (2.6–3.1) 0.84 (0.74–0.96)
CRB 798 3.3 (3.1–3.6) 1001 4.0 (3.7–4.2) 0.83 (0.76–0.91) 787 4.4 (4.1–4.7) 975 4.9 (4.6–5.3) 0.89 (0.81–0.98)
Death (all causes) 902 3.9 (3.7–4.2) 1414 5.8 (5.5–6.1) 0.67 (0.61–0.73) 1565 9.1 (8.6–9.5) 2069 10.8 (10.3–11.2) 0.85 (0.79–0.90)
Composite criterion 
(SSE, MB, and death)
1489 6.3 (6.0–6.6) 2217 8.9 (8.5–9.2) 0.70 (0.65–0.74) 2189 12.5 (12.0–13.0) 2738 14.0 (13.5–14.5) 0.89 (0.84–0.94)
Acute coronary 
syndrome
286 1.2 (1.0–1.3) 374 1.4 (1.3–1.6) 0.80 (0.69–0.93) 270 1.5 (1.3–1.7) 347 1.7 (1.6–1.9) 0.85 (0.73–1.00)
CRB indicates clinically relevant bleeding; HR, hazard ratio; MB, major bleeding; R15, rivaroxaban 15 mg; R20, rivaroxaban 20 mg; SSE, stroke and systemic 
embolism; and VKA, vitamin K antagonist.




 http://ahajournals.org by on January 15, 2021
Blin et al  Rivaroxaban 15 or 20 mg vs VKA in Atrial Fibrillation  2475
identical to within <5% of standardized mean differences in all 
variables, including all measurable bleeding and embolism risk 
factors, as well as common fatality risks, medical history, and 
drug dispensings. The differences between crude and matched 
results indicate the degree to which biases were corrected. The 
hdPS distribution curves overlapped over the whole population 
range, so that results in the matched population could be safely 
extrapolated to the whole population, as indicated by the sim-
ilar results in matched and adjusted populations.
hdPS matching has been used in many pharmacoepidemi-
ology studies. Unmeasured confounders such as smoking and 
obesity may be captured by various combinations of claims 
such as visits, prescriptions, procedures, tests, and hospitaliza-
tions, which may collectively be a proxy for risk factors that 
are not present as such in the database.27,28
The data in SNDS are collected prospectively and inde-
pendently for healthcare insurance purposes, excluding infor-
mation bias. Data are present for the whole population, with 
no selection according to social status, employer, age, or pre-
existing conditions.14 There are no sampling issues because 
the whole population is captured. All outpatient use of anti-
coagulants is identified. Drugs are dispensed as fixed prepara-
tions (eg, rivaroxaban, 20 mg per capsule, 30 capsules) that 
are individually identified, providing the exact quantity and 
dosage dispensed.
Diagnoses are based on hospital discharge summaries and 
on registration for chronic diseases and any other available 
data such as drug dispensings or procedures. The same meth-
ods and diagnostic algorithms were used in other studies of 
VKA and direct-acting oral anticoagulant for NVAF.4,15,16,18,34 
The identification of all-cause death is exhaustive.
Our results are generally consistent with other epidemio-
logical studies done in different settings, and different med-
ical environments, generally showing fewer SSEs, bleeding, 
and deaths than VKA. However, a Danish nationwide analysis 
by Larsen et al35 found a markedly higher risk of death with 
R15 compared with matched VKA (hazard ratio, 1.52).36 Our 
results obtained in a larger study show a lower risk of death 
with R15 than matched VKA.
In Taiwan, where lower doses of rivaroxaban are used 
(15 mg, 10 mg), both doses were associated with lower event 
rates of SSE, bleeding, and all-cause death than VKA—a find-
ing shared with other studies.13,37–40
Other population-based studies did not compare rivar-
oxaban to VKA or differentiate doses.11,41–43 The populations 
were relatively small, with 2000 to fewer than 6000 patients 
included, resulting in large CIs. However, point estimates for 
hazard ratio were not different from those found here.
Whether differences between studies are related to a dif-
ferent approach to the use of VKA,44 to different healthcare 
systems, different sets of patients treated, or to a different sta-
tistical approach may be debated.
We did not directly compare R15 with R20, which were 
used in different populations.
Conclusions
In this real-life countrywide hdPS-matched new users cohort 
study, rivaroxaban appears to be at least as effective (R15) or 
more effective (R20) and for both doses safer than VKA for 
the prevention of thromboembolic events in NVAF.
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